

**Original citation:**

Innominato, Pasquale F., Spiegel, David, Ulusakarya, Ayhan, Giacchetti, Sylvie, Bjarnason, Georg A., Lévi, Francis A. and Palesh, Oxana. (2015) Subjective sleep and overall survival in chemotherapy-naïve patients with metastatic colorectal cancer. *Sleep Medicine*, 16 (3). pp. 391-398.

**Permanent WRAP URL:**

<http://wrap.warwick.ac.uk/85120>

**Copyright and reuse:**

The Warwick Research Archive Portal (WRAP) makes this work by researchers of the University of Warwick available open access under the following conditions. Copyright © and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable the material made available in WRAP has been checked for eligibility before being made available.

Copies of full items can be used for personal research or study, educational, or not-for-profit purposes without prior permission or charge. Provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.

**Publisher's statement:**

© 2015, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International <http://creativecommons.org/licenses/by-nc-nd/4.0/>

**A note on versions:**

The version presented here may differ from the published version or, version of record, if you wish to cite this item you are advised to consult the publisher's version. Please see the 'permanent WRAP url' above for details on accessing the published version and note that access may require a subscription.

For more information, please contact the WRAP Team at: [wrap@warwick.ac.uk](mailto:wrap@warwick.ac.uk)

**Subjective sleep and overall survival in chemotherapy-naïve patients with metastatic colorectal cancer.**

Pasquale F. Innominato,<sup>1,2</sup> David Spiegel,<sup>3,4</sup> Ayhan Ulusakarya,<sup>1,2</sup> Sylvie Giacchetti,<sup>2,5</sup> Georg A. Bjarnason,<sup>6</sup> Francis Lévi<sup>1,2,7,8</sup> and Oxana Palesh<sup>3,4</sup>

1. Assistance Publique – Hôpitaux de Paris, Department of Oncology, Paul Brousse Hospital, Villejuif, France

2. INSERM, UMRS 776 “Rythmes Biologiques et Cancers”, Villejuif, France

3. Center for Stress and Health, Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, United States of America

4. Stanford Cancer Institute, Stanford, CA, United States of America

5. Breast Diseases Unit, Department of Medical Oncology, Assistance Publique – Hôpitaux de Paris, St. Louis Hospital, Paris, France

6. Division of Medical Oncology, Sunnybrook Odette Cancer Center, Toronto, Ontario, Canada

7. Université Paris Sud 11, UMR-S0776, Orsay, France

8. Cancer Chronotherapy Unit, Warwick Medical School, Warwick University, Coventry, Warwickshire, United Kingdom

Corresponding Author: Pasquale F. Innominato, MD, PhD

INSERM U776 “Biological rhythms and cancer”

Campus CNRS

Bat A 3ème étage

7 rue Guy Moquet

94801 Villejuif cedex

France

Tel : 33 1 49 58 34 79

Fax : 33 1 49 58 34 59

pasquale.innominato@inserm.fr

**Conflicts of interest: None**

Acknowledgments:

We sincerely thank all the patients who participated in this study, the investigators who enrolled patients in the European Organization for Research and Treatment of Cancer (EORTC) 05963 trial, and Marie-Ange Lentz from the EORTC Data Center (Brussels, Belgium) for her excellent data managing efforts. The study was supported in part by the Association Internationale pour la Recherche sur le Temps Biologique et la Chronotherapie (ARTBC International), Paul Brousse Hospital, Villejuif, France.

This study was presented in part at the MASCC/ISOO International Symposium on Supportive Care in Cancer (Berlin, Germany, June 27<sup>th</sup>-29<sup>th</sup>, 2013) and at the ASCO Gastrointestinal Cancers Symposium (San Francisco, CA, United States of America, January 16<sup>th</sup>-18<sup>th</sup>, 2014).

Keywords:

Sleep, colorectal cancer, survival, circadian, chronotherapy, prognosis, time-dependent covariates, FOLFOX, quality of life

Running Title: Sleep and metastatic colon cancer survival

## **ABSTRACT**

**Background:** Sleep disorders are prevalent in patients with advanced cancer. Their impact on clinical outcomes is not well understood.

**Methods:** A post-hoc analysis was conducted in 361 patients previously untreated for metastatic disease with metastatic colorectal cancer completing twice the EORTC QLQ-C30 questionnaire within a randomized international phase III trial. The study assessed the effect on overall survival (OS) of subjective sleep complaint, used as a normal or a time-dependent covariate (TDC), using a multivariate Cox proportional hazard model. Prognostic analysis was conducted on the whole study population and separately in each treatment arm (conventional FOLFOX2, or chronomodulated chronoFLO4).

**Results:** Sleep problems were reported by 202 patients (56%) at baseline and by 188 (52%) on treatment. Sleep problems at baseline were independently associated with a higher risk of earlier death (HR: 1.36;  $p=0.011$ ), progression (HR: 1.43;  $p=0.002$ ) and poor treatment response (RR: 0.58;  $p=0.016$ ). TDC analysis confirmed the independent prognostic effect of sleep problems on OS (HR: 1.37;  $p=0.008$ ), while on treatment this effect was only observed using univariate analysis. The negative prognostic value of sleep problems on OS, at baseline, on treatment and as a TDC, was greatest on chronoFLO4 compared to FOLFOX2.

**Conclusions:** Subjective sleep problems are associated with poor clinical outcomes in metastatic colorectal cancer patients and affect effectiveness of chronomodulated chemotherapy. There is a need for a well-tuned circadian timing system in order to increase chronomodulated chemotherapy activity. Prospective studies are needed for determining the impact of therapeutic approaches on sleep disorders upon quality of life and survival of cancer patients.

## INTRODUCTION

Sleep problems are prevalent in cancer patients and survivors, with nearly two-thirds of patients reporting them <sup>1-4</sup>. However, relatively little is known about sleep disorders in colorectal cancer patients. In a study of 157 adults with colon or rectal cancer, sleep problems were reported by 35% of patients, and higher levels of sleep problems predicted for more fatigue, together with more depression and poorer performance status <sup>5</sup>. In another small study involving 21 patients with colorectal cancer undergoing adjuvant chemotherapy, clinically significant sleep disturbance was observed <sup>6</sup>. Berger et al. also noted substantial evidence of circadian disruption in that sample, suggesting that patients diagnosed with these types of cancer experience lack of distinction between nighttime and daytime in their activities <sup>6</sup>. This phenomenon was previously described in patients with advanced cancers where substantial amount of time spent asleep during the day and awake during the night effectively blurs the line between day and nighttime <sup>7-9</sup>. The observed association between altered rest-activity rhythm and subjectively-reported sleep problems in two independent cohorts of patients with metastatic colorectal cancer <sup>10, 11</sup> further supported the hypothesis that disruption of circadian rhythms in cancer patients plays a role in the occurrence of sleep problems. .

Evidence from several epidemiological studies suggests that chronic circadian disruption is carcinogenic and associated with increased risk of many cancers, including colorectal cancer <sup>12, 13</sup>. Sleep disorders have also been reported to be associated with numerous adverse psychiatric and health outcomes, including neurocognitive, metabolic, endocrine, and immune effects, increased fatigue, decreased physical activity, drowsiness, anxiety, depression, and increased perception of pain<sup>14-16</sup>. These data point to circadian disruption as a potential mechanism for sleep problems and the associated health risks.

Despite this scientific evidence and the common knowledge of adverse health associated with disturbed sleep, data on large populations of cancer patients are lacking with regard to the effects of sleep problems on clinical outcomes. Nonetheless, other patient-reported symptoms have been more extensively studied

and their importance as independent prognostic factors in various cancers, including advanced colorectal cancer, has been confirmed<sup>1, 17-22</sup>.

We examined the prognostic role of subjective sleep complaints before and during chemotherapy in patients diagnosed with metastatic colorectal cancer using data from a randomized controlled trial conducted by the European Organisation for Research and Treatment of Cancer (EORTC) Chronotherapy Group.

## **PATIENTS and METHODS**

### **Study Objective and Design**

This clinical trial enrolled 564 patients previously untreated for metastatic disease from 36 centers in 10 countries between October 1998 and February 2002; 282 patients were randomly assigned to one of the following treatment arms: FOLFOX2 or chronoFLO4<sup>23</sup> (Figure 1). Both regimens combined oxaliplatin, 5-fluorouracil, and leucovorin, administered with either a conventional, non-time stipulated 2-day delivery (FOLFOX2), or with a chronomodulated, circadian-based infusion for 4 days (chronoFLO4). The description of these schedules, the patient inclusion and exclusion criteria, and the report of overall outcomes of the trial have been detailed elsewhere<sup>23</sup>. The study, approved by the EORTC protocol review committee and the ethics committee of each participating center, was conducted in compliance with the Helsinki declaration. All patients provided written informed consent.

### **Sleep Assessment**

Patients' subjective sleep was measured using the corresponding scale of a multidimensional questionnaire of HRQoL, the EORTC Quality of Life Questionnaire C30 (QLQ-C30), version 2.0<sup>24</sup>. Assessments were performed at baseline (before chemotherapy start, but after a variable amount of time since initial cancer diagnosis and staging workup) and during protocol chemotherapy (every 4<sup>th</sup> cycle of chemotherapy, about 2 months apart). The sleep score from EORTC QLQ-C30 was calculated using the recommended EORTC procedures<sup>24</sup> and involved the transformation of raw scores of increased severity into a linear scale ranging from 0 to 100. In particular, the EORTC QLQ-C30 questionnaire involves one straightforward question: "[During the past week] Have you had trouble sleeping?" We considered that patients had no subjective sleep complaints if they answered "not at all"

(corresponding to 0 on the scale). The other values of the scale (i.e., 33.3, 66.7 or 100, corresponding to “a little”, “quite a bit” and “very much”, respectively) were considered a subjective report of sleep problems.

### **Statistical Analysis**

The primary endpoint of this study was the association between subjective sleep complaints and overall survival (OS). We explored this association using sleep scores at baseline, while on treatment, and as time-dependent covariates (TDC). In each case, OS was measured from the date of completion of the corresponding questionnaire to the date of death (due to any cause). Patients still alive at the time of database locking were censored at the last date known to be alive. Similarly, time to progression (TTP) was calculated from the date of questionnaire completion until the date of disease progression or death, whichever occurred first.

Survival curves and probabilities were estimated using the Kaplan-Meier technique, and differences between survival curves were assessed using the log-rank test. The Cox proportional hazards regression model was used for both univariate and multivariate analyses of survival. For the prognostic analysis, the subjective sleep complaint was used either as a simple variable or as a time-dependent covariate. A multivariate prognostic model was then built, forcedly entering other possible prognostic factors. The added adjusting factors included: randomized treatment, age, sex, site of primary tumor, resection of primary tumor, Duke’s stage at diagnosis, prior adjuvant chemotherapy, World Health Organization (WHO) performance status (PS) at baseline, number of metastatic sites, body mass index (BMI) at baseline, anemia, leukocytosis, and elevated alkaline phosphatases or lactate dehydrogenase (LDH) <sup>25</sup>. For survival analysis using sleep data during treatment, PS and BMI at day 1 of the corresponding chemotherapy cycle of questionnaire completion were used instead of baseline values. In this latter model, the number of chemotherapy cycles received was also entered in the final Cox model. All analyses were performed in the whole study population and subsequently, in each treatment arm separately. Moreover, exploratory subgroup analyses were performed to observe differences in the prognostic significance of subjective sleep complaints on OS.

The best objective tumor response (OR) was assessed using WHO criteria. Univariate and multivariate binary logistic regression was used to assess the predictive role of baseline sleep complaints on response rate.

Baseline clinical and demographic factors associated with subjective sleep complaints were explored using 2-sided Chi-square (for categorical variables) or Wilcoxon t-test (for quantitative variables). The level of statistical significance was set at  $p < 0.05$ . All analyses were performed using PASW 16 software (SPSS Inc., USA).

## **RESULTS**

### **Demographics and biomedical characteristics of study patients**

Out of the 564 enrolled patients, 361 patients (64%) had available sleep assessment both at baseline and at least one during treatment. . Demographics and biomedical characteristics in the current study population (n=361), summarized in Table 1, were comparable to those of the whole population of the EORTC 05963 trial (data not shown)<sup>23</sup>.

The interval between baseline sleep assessment and the last HRQoL assessment while on treatment is shown in Figure 1.

### **Prevalence of subjective sleep problems at baseline and on treatment**

Prevalence of sleep problems is shown in Figure 1. There were no differences between treatment arms concerning sleep problems reported at either baseline or during treatment.

Overall, 131 patients (36.3%) reported sleep problems at both assessments (baseline and while receiving treatment); no mention of sleep problems was recounted by 102 patients (28.3%) at both assessments. New onset sleep problems were reported by 57 patients (15.8%), and 71 patients (19.7%) experienced sleep remission while receiving chemotherapy. These figures were comparable in patients on FOLFOX2 and on chronoFLO4 ( $p=0.74$ ; data not shown).



### **Clinical and demographic factors associated with subjective sleep problems**

Out of the entire baseline clinical factors screened, only female sex ( $p=0.023$ ) and poor PS ( $p=0.002$ ) were significantly associated with baseline sleep problems (Table 1). Thus, sleep problems were more prevalent in females than in males, and in patients with poorer PS as compared to those with better PS=0, both at baseline and on treatment ( $p=0.018$  and  $p=0.01$ , respectively).

### **Relationships between patient-reported sleep problems and clinical outcomes**

The presence of subjective sleep complaints at baseline was associated with a 39% higher risk of earlier death (95% confidence interval [CI]: 11% to 74%;  $p=0.0034$ ), a 44% higher risk of earlier disease progression (16% to 78%;  $p=0.0009$ ), and a 42% lower chance of obtaining an objective response (complete or partial) (11% to 62%;  $p=0.011$ ) (Figure 2). Thus, median overall survival in patients with sleep complaints at baseline was 19.1 months (95% CI: 16.6 to 21.7 months) as compared to 21.7 months (18.6 to 24.8 months) in patients not reporting sleep complaints at baseline. Similarly, median time to progression was 8.3 (7.5 – 9.0) and 10.0 months (8.9 – 11.1), respectively, in patients with and without sleep problems at baseline. Finally, objective response rate was 45.1% (95% CI: 38.3 – 51.9%) among patients with sleep problems at baseline compared to 58.5% (50.7 – 65.9%) in patients without sleep problems at baseline (Figure 2).

Persisting or newly appeared sleep complaints during treatment were significantly associated with shorter survival. In patients with sleep problems, median overall survival was 14.1 months (12.6 – 15.5), compared to 15.8 months (13.2 – 18.4) in patients without sleep problems (data not shown; HR: 1.27; 95% CI: 1.02 to 1.58;  $p=0.036$ ). Moreover, when subjective sleep complaints were considered as time-dependent covariate, their presence predicted significantly shorter overall survival (HR: 1.30; 95% CI: 1.05 to 1.63;  $p=0.019$ ).

Following adjustment for other known prognostic factors, baseline sleep problems remained independently and significantly associated with shorter overall survival, with an estimated 36% (95% CI: 7% – 72%) increased risk of an earlier death ( $p=0.011$ ) (Table 2). The final model included baseline PS, number of metastatic sites, and elevated LDH values (Table 2). Similarly, baseline sleep problems

remained in the multivariate models, independently predicting both shorter time to progression (HR: 1.43; 95% CI: 1.13-1.79; p=0.002) and lower objective response rate (RR: 0.58; 95%CI: 0.37-0.90; p=0.016) (data not shown).

The multivariate model, with sleep problems considered as time-dependent covariate, confirmed the independent prognostic value of patient-reported altered sleep on overall survival, with an estimated increased risk roughly unchanged following adjustment for other possible prognostic factors (HR: 1.37; 95% CI: 1.08 to 1.72; p=0.008) (Table 2.). The other variables in the final models were the same as in the previous one (i.e., baseline PS, number of metastatic sites, and LDH) (Table 2).

Conversely, the presence of sleep problems at the last available assessment while on treatment protocol was not associated with an independent and significantly higher risk of earlier death (p=0.234). The main prognostic factor was PS at the date of the last questionnaire completion, along with the number of metastatic sites and LDH (Table 2).

Overall, exploratory subgroup analyses showed consistently increased risk for an earlier death in all subgroups tested associated with subjective sleep complaints, whether used as a simple variable or as a time-dependent covariate (Figure 3).

### **Differences of survival prognostic models according to treatment arm**

Patients with subjective report of sleep problems at baseline displayed significantly shorter survival, regardless of the treatment schedule that they subsequently received. Indeed, on FOLFOX2, the median overall survival was 17.7 months (15.8 – 19.5) in patients reporting sleep problems and 22.6 months (15.9 – 29.3) in patients without sleep problems. Respective corresponding median overall survival values on chronoFLO4 were 20.9 months (17.8 – 24.0) and 21.3 months (18.5 – 24.1) (Figure 4). This translated into a highly similar hazard ratio for earlier death (HR=1.41; 95% CI: 1.04 to 1.93; p=0.029 on FOLFOX2; HR=1.40; 95% CI: 1.02 to 1.93; p=0.04 on chronoFLO4, respectively). In multivariate analyses, baseline subjective sleep problems were associated with a significant shorter survival only in patients receiving chronoFLO4 (p=0.012) (Table 3). In patients receiving FOLFOX2, the survival difference was approaching statistical significance (p=0.056) (Table 3).

Subjective sleep problems observed at the last valid assessment while on treatment, were significantly associated with a shorter survival in patients on chronoFLO4 ( $p=0.009$ ), and not in those treated with FOLFOX2 ( $p=0.75$ ) (Figure 4; Table 3). Thus, median overall survival was similar in patients on FOLFOX2, regardless of the occurrence (13.6 months; 95% CI: 11.7 – 15.6) or not (15.0 months; 11.6 – 18.3) of sleep problems while on treatment ( $p=0.75$ ). Meanwhile, overall survival was significantly longer in patients without sleep problems (16.7 months; 11.9 – 21.5) as compared to those complaining of having sleep problems (14.5 months; 11.9 – 17.1) while receiving chronoFLO4 ( $p=0.009$ ) (Figure 4). However, on multivariate analysis, this survival difference did not reach statistical significance ( $p=0.088$ ) (Table 3).

This difference between treatment regimens and the effect of subjective sleep problems on overall survival while on treatment was confirmed by time-dependent covariate analysis, showing a significant association between sleep problems with shorter overall survival on chronoFLO4 ( $p=0.006$ ), but not on FOLFOX2 ( $p=0.54$ ) (Table 3). In patients treated with chronoFLO4, subjective sleep problems, treated as time-dependent covariate, independently predicted earlier death, even after adjusting for other possible prognostic factors ( $p=0.001$ ) (Table 3).

## **DISCUSSION**

In this study, we showed for the first time that reported good sleep, as measured using a single subjective questionnaire item, was associated with better clinical outcomes in patients with metastatic colorectal cancer. We found that 44% of patients who reported no sleep complaints before chemotherapy treatment (but after diagnosis of metastatic disease) had a median 2-month increase in overall survival and time to progression. In addition, these patients had an objective response rate about 13.5% higher than patients complaining of sleep problems. These positive prognostic effects of good sleep remained significant even after adjusting for other known prognostic factors or subgroups. These results further emphasize the clinical relevance of poor sleep in cancer patients, which has previously been associated with fatigue, mood disorders, poor functioning, and worse quality of life<sup>14, 15</sup>. Sleep problems, however, remain an overlooked issue in cancer patients, despite the known negative effects of poor sleep quality and quantity in cancer-free populations, where they represent a relevant social and health issue<sup>26-28</sup>.

This study did not examine the potential mechanism of action behind sleep and survival. Sleep-wake cycles and circadian rhythms, especially that of rest and activity, are closely linked <sup>1, 29</sup>. An alteration of the circadian rest-activity rhythm has been shown to be an independent negative prognostic factor in survival in three separate studies involving patients with advanced colorectal cancer <sup>10, 11, 30, 31</sup>. These studies have also confirmed the correlation between subjective sleep complaints, (measured with the single item of the EORTC questionnaire), and a clinically relevant circadian actigraphy parameter, the dichotomy index I<O <sup>10, 11</sup>. As such, the current findings are in agreement with the hypothesis that altered sleep (and circadian function), either before the start of treatment or during chemotherapy are associated with poorer outcomes in cancer patients <sup>32</sup>, and in good agreement with experimental evidence in laboratory animals <sup>33</sup>. Furthermore, a recent clinical study further found that objectively measured poor sleep efficiency was an independent poor prognostic indicator for survival in advanced breast cancer patients <sup>34</sup>. Thus, our findings support the clinical relevance of regular circadian rhythms, including sleep-wake cycles, in advanced cancer patients undergoing treatment <sup>32</sup>.

Our subgroup analyses furthermore substantiate the hypothesis that excessive toxicity could hamper the efficacy of circadian-based chronomodulated chemotherapy <sup>8, 30, 32, 33, 35, 36</sup>. In this study, we found that the complaint of sleep troubles at the last on-treatment assessment was correlated with shorter overall survival in patients treated with chronoFLO4, but not on FOLFOX2. Analysis using sleep problems as a time-dependent covariate confirmed that the negative prognostic value of sleep complaints was limited to patients on chronoFLO4. Thus, our findings underscore the hypothesis that optimal efficacy of circadian-based chronotherapy is associated with optimal tolerability <sup>32, 33, 37</sup>. Indeed, the persistence of robust circadian function during chemotherapy, a recently documented phenomenon <sup>38</sup>, associated with lower incidence and/or severity of chemotherapy toxicity, has been shown to predict for better efficacy of chronotherapy <sup>8, 30, 32, 33, 35, 36</sup>. Thus, as for severe neutropenia or clinically meaningful fatigue and/or weight loss, subjective sleep complaints during treatment might reflect disrupted circadian function, decreasing chronotherapy effectiveness.

In this study, we screened for subjective sleep complaints using an item from a validated and widely used HRQoL questionnaire, with translations available in every

suitable language for the study population <sup>24, 39</sup>. The EORTC QLQ-C30 evaluates sleep with a single question, as part of a multidimensional patient-rated questionnaire. Given the various forms of possible sleep troubles, the use of a single item, although validated for this assessment, constitutes a limitation of this study. Another limitation is the compliance rate, which was suboptimal, as only 64% of patients provided sleep data for the current study.

The strengths of this study include a large sample size, the prospective collection of data, and a homogeneous population of patients previously untreated for metastatic disease. Our present findings are in agreement with recent results in women with advanced breast cancer <sup>34</sup>, and provide insight into the relationship between sleep, circadian rhythms, chemotherapy toxicity, and clinical outcomes in cancer patients.

Disturbed sleep is related to circadian disruption, and both sleep disorders and circadian disruption have detrimental effects on immunity and metabolic processes <sup>14, 28, 32, 37, 40</sup>. The alleviation of sleep complaints through behavioral and/or pharmacologic interventions could potentially improve circadian function, and jointly enhance both quality of life and overall survival. Therefore, future research is warranted in an attempt to improve sleep and circadian function in cancer patients, using cognitive-behavioral approaches and/or chronobiotic agents <sup>15, 32</sup>.

**Table 1.**

Clinical and demographic features of the whole study population, and separately according to the presence or not of subjective sleep complaints at baseline.

Variable		Total study population (N=361)	Sleep complaints	
			No (N=159)	Yes (N=202)
		No. (%)	No. (%)	No. (%)
Age	Median	62.0	61.1	62.2
	(range)	(22.3-75.9)	(34.5-75.5)	(22.3-75.9)
Randomized treatment	FOLFOX2	188 (52.1)	82 (51.6)	106 (52.5)
	chronoFLO4	173 (47.9)	77 (48.4)	96 (47.5)
Sex	Female	140 (38.8)	51 (32.1)	89 (44.1)
	Male	221 (61.2)	108 (67.9)	113 (55.9)

<b>Primary tumor</b>	Colon	348 (96.4)	155 (97.5)	193 (95.5)
	Resected	312 (86.4)	136 (85.5)	176 (87.1)
<b>Prior adjuvant chemotherapy</b>	Yes	67 (18.6)	31 (19.5)	34 (16.8)
<b>Synchronous metastases</b>	Yes	268 (74.2)	114 (71.7)	154 (76.2)
<b>Number of metastatic sites</b>	1	146 (40.4)	69 (43.4)	77 (38.1)
	2	133 (36.8)	52 (32.7)	81 (40.1)
	≥ 3	82 (22.7)	38 (23.9)	44 (21.8)
<b>PS (WHO)</b>	0	180 (49.9)	96 (60.4)	84 (41.6)
	1	147 (40.7)	52 (32.7)	95 (47.0)
	2	34 (9.4)	11 (6.9)	23 (11.4)
<b>Body Mass Index (Kg/m<sup>2</sup>)</b>	Normal (18.5-24.9)	181 (50.1)	73 (45.9)	108 (53.5)
	Abnormal (<18.5 or > 25.0)	180 (49.9)	86 (54.1)	94 (46.5)
<b>Baseline Biology</b>	Hb < 12 g/dL	144 (39.9)	60 (37.7)	84 (41.6)
	WBC > 10*10 <sup>9</sup> /L	84 (23.3)	31 (19.5)	53 (26.2)
	ALP > 300 IU/L	82 (22.7)	34 (21.4)	48 (23.8)
	LDH > 2x ULN	127 (35.2)	55 (34.6)	72 (35.6)

Note: PS (WHO)-Performance Status, Hb-Haemoglobin, WBC-white blood count, ALP-Alkaline Phosphatases, LDH-Lactate Dehydrogenases

**Table 2.**

Final multivariate proportional Cox regression hazard models for overall survival with subjective sleep complaints at baseline, on treatment, and as time-dependent covariate, in the whole study population.

<b>Variable</b>		<b>HR (95% CI)</b>	<b>P</b>
<b>At baseline</b>			
<b>Sleep complaints</b>	<b>No</b>	1	<i>0.011</i>
	<b>Yes</b>	1.36 (1.07-1.72)	
<b>WHO PS</b>	<b>0</b>	1	<i>0.010</i>
	<b>1</b>	1.33 (1.03-1.72)	

	<b>2</b>	1.91 (1.22-2.99)	
<b>No. of metastatic sites</b>	<b>1</b>	1	<i>&lt;0.0001</i>
	<b>2</b>	1.52 (1.15-2.00)	
	<b>≥ 3</b>	3.05 (2.21-4.20)	
<b>LDH</b>	<b>≤ 2x ULN</b>	1	<i>0.016</i>
	<b>&gt; 2x ULN</b>	1.33 (1.02-1.75)	
	<b>Unknown</b>	1.69 (1.11-2.57)	
<b>On treatment</b>			
<b>Sleep complaints</b>	<b>No</b>	1	<i>0.234</i>
	<b>Yes</b>	1.16 (0.91-1.48)	
<b>No. of metastatic sites</b>	<b>1</b>	1	<i>&lt; 0.0001</i>
	<b>2</b>	1.49 (1.12-1.98)	
	<b>≥ 3</b>	2.73 (1.96-3.82)	
<b>LDH</b>	<b>≤ 2x ULN</b>	1	<i>0.010</i>
	<b>&gt; 2x ULN</b>	1.45 (1.09-1.93)	
	<b>Unknown</b>	1.66 (1.09-2.55)	
<b>WHO PS (at day 1 of the cycle of last questionnaire)</b>	<b>0</b>	1	<i>&lt; 0.0001</i>
	<b>1</b>	1.62 (1.22-2.15)	
	<b>2</b>	2.18 (1.37-3.47)	
	<b>3</b>	9.70 (1.24-76.1)	
<b>As time-dependent covariate</b>			
<b>Sleep complaints</b>	<b>No</b>	1	<i>0.008</i>
	<b>Yes</b>	1.37 (1.08-1.72)	
<b>WHO PS (at baseline)</b>	<b>0</b>	1	<i>0.002</i>
	<b>1</b>	1.41 (1.09-1.82)	
	<b>2</b>	2.09 (1.34-3.26)	
<b>No. of metastatic sites</b>	<b>1</b>	1	<i>&lt; 0.0001</i>
	<b>2</b>	1.51 (1.15-1.98)	
	<b>≥ 3</b>	3.01 (2.19-4.14)	

<b>LDH</b>	<b>≤ 2x ULN</b>	1	<i>0.013</i>
	<b>&gt; 2x ULN</b>	1.40 (1.06-1.84)	
	<b>Unknown</b>	1.64 (1.08-2.49)	

**Table 3.**

Univariate and multivariate Hazard ratios (95% CI) for overall survival of subjective sleep complaints at baseline, on treatment, and as time-dependent covariate, separately in the FOLFOX2 and chronoFLO4 treatment arms.

Subjective sleep complaints (yes)	<b>FOLFOX2</b>				<b>chronoFLO4</b>			
	<b>Univariate</b>		<b>Multivariate</b>		<b>Univariate</b>		<b>Multivariate</b>	
	<b>HR</b>	<b><i>P</i></b>	<b>HR</b>	<b><i>p</i></b>	<b>HR</b>	<b><i>p</i></b>	<b>HR</b>	<b><i>p</i></b>
<b>At baseline</b>	1.41 (1.04- 1.93)	<b><i>0.029</i></b>	1.40 (0.99- 1.97)	<i>0.056</i>	1.40 (1.02- 1.93)	<b><i>0.040</i></b>	1.60 (1.11- 2.32)	<b><i>0.012</i></b>
<b>On treatment</b>	1.05 (0.78- 1.43)	<i>0.75</i>	1.20 (0.82- 1.74)	<i>0.35</i>	1.53 (1.11- 2.11)	<b><i>0.009</i></b>	1.38 (0.95- 2.01)	<i>0.088</i>
<b>As time- dependent covariate</b>	1.10 (0.81- 1.49)	<i>0.54</i>	1.27 (0.90- 1.78)	<i>0.18</i>	1.57 (1.14- 2.17)	<b><i>0.006</i></b>	1.74 (1.24- 2.44)	<b><i>0.001</i></b>



## **FIGURE LEGENDS**

### **Figure 1.**

Study flow-chart.

### **Figure 2.**

Clinical outcomes according to baseline sleep complaints (red: yes; yellow: no). Left panel: Kaplan-Meier curves for overall survival. Middle panel: Kaplan-Meier curves for time to progression. Right panel: objective response rate (complete and partial, WHO criteria), with 95% confidence interval. HR: hazard ratio. OR: odds ratio. Results presented for univariate analyses.

### **Figure 3.**

Forrest plot for overall survival, indicating the hazard ratio (and 95% confidence interval) of an earlier death, obtained with univariate Cox proportional regression hazard models, according to the presence of subjective sleep complaints either at baseline (left panel) or as time-dependent covariate (right panel).

### **Figure 4.**

Kaplan-Meier curves for overall survival in patients on FOLFOX2 (left panels) or on chronoFLO4 (right panels), according to sleep complaints (red: yes; yellow: no) at baseline (top panels), or at the last assessment while on treatment (bottom panels).

## REFERENCES

1. Palesh O, Peppone L, Innominato PF, et al. Prevalence, Putative Mechanisms and Management of Sleep Problems During Chemotherapy. *Nature and Science of Sleep*. 2012;4: 151162.
2. Howell D, Oliver TK, Keller-Olaman S, et al. Sleep disturbance in adults with cancer: a systematic review of evidence for best practices in assessment and management for clinical practice. *Ann Oncol*. 2014;25: 791-800.
3. Howell D, Oliver TK, Keller-Olaman S, et al. A Pan-Canadian practice guideline: prevention, screening, assessment, and treatment of sleep disturbances in adults with cancer. *Support Care Cancer*. 2013;21: 2695-2706.
4. Palesh OG, Roscoe JA, Mustian KM, et al. Prevalence, demographics, and psychological associations of sleep disruption in patients with cancer: University of Rochester Cancer Center-Community Clinical Oncology Program. *J Clin Oncol*. 2010;28: 292-298.
5. Mota DD, Pimenta CA, Caponero R. Fatigue in colorectal cancer patients: prevalence and associated factors. *Rev Lat Am Enfermagem*. 2012;20: 495-503.
6. Berger AM, Grem JL, Visovsky C, Marunda HA, Yurkovich JM. Fatigue and other variables during adjuvant chemotherapy for colon and rectal cancer. *Oncol Nurs Forum*. 2010;37: E359-369.
7. Parker KP, Bliwise DL, Ribeiro M, et al. Sleep/Wake patterns of individuals with advanced cancer measured by ambulatory polysomnography. *J Clin Oncol*. 2008;26: 2464-2472.
8. Innominato PF, Mormont MC, Rich TA, Waterhouse J, Levi FA, Bjarnason GA. Circadian disruption, fatigue, and anorexia clustering in advanced cancer patients: implications for innovative therapeutic approaches. *Integr Cancer Ther*. 2009;8: 361-370.
9. Palesh O, Zeitzer JM, Conrad A, et al. Vagal regulation, cortisol, and sleep disruption in women with metastatic breast cancer. *J Clin Sleep Med*. 2008;4: 441-449.
10. Mormont MC, Waterhouse J, Bleuzen P, et al. Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status. *Clin Cancer Res*. 2000;6: 3038-3045.
11. Innominato PF, Focan C, Gorlia T, et al. Circadian rhythm in rest and activity: a biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer. *Cancer Res*. 2009;69: 4700-4707.
12. Schernhammer ES, Laden F, Speizer FE, et al. Night-shift work and risk of colorectal cancer in the nurses' health study. *J Natl Cancer Inst*. 2003;95: 825-828.
13. Zhang X, Giovannucci EL, Wu K, et al. Associations of self-reported sleep duration and snoring with colorectal cancer risk in men and women. *Sleep*. 2013;36: 681-688.
14. Foster RG, Wulff K. The rhythm of rest and excess. *Nat Rev Neurosci*. 2005;6: 407-414.
15. Palesh O, Aldridge-Gerry A, Ulusakarya A, Ortiz-Tudela E, Capuron L, Innominato PF. Sleep disruption in breast cancer patients and survivors. *J Natl Compr Canc Netw*. 2013;11: 1523-1530.
16. Aldridge-Gerry A, Zeitzer JM, Palesh OG, et al. Psychosocial correlates of sleep quality and architecture in women with metastatic breast cancer. *Sleep Med*. 2013;14: 1178-1186.
17. Quinten C, Martinelli F, Coens C, et al. A global analysis of multitrail data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites. *Cancer*. 2014;120: 302-311.




18. Quinten C, Maringwa J, Gotay CC, et al. Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival. *J Natl Cancer Inst.* 2011;103: 1851-1858.
19. Quinten C, Coens C, Mauer M, et al. Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. *Lancet Oncol.* 2009;10: 865-871.
20. Efficace F, Innominato PF, Bjarnason G, et al. Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Research and Treatment of Cancer. *J Clin Oncol.* 2008;26: 2020-2026.
21. Gotay CC, Kawamoto CT, Bottomley A, Efficace F. The prognostic significance of patient-reported outcomes in cancer clinical trials. *J Clin Oncol.* 2008;26: 1355-1363.
22. Efficace F, Bottomley A, Coens C, et al. Does a patient's self-reported health-related quality of life predict survival beyond key biomedical data in advanced colorectal cancer? *Eur J Cancer.* 2006;42: 42-49.
23. Giacchetti S, Bjarnason G, Garufi C, et al. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group. *J Clin Oncol.* 2006;24: 3562-3569.
24. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. *J Natl Cancer Inst.* 1993;85: 365-376.
25. Kohne CH, Cunningham D, Di CF, et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. *Ann Oncol.* 2002;13: 308-317.
26. Leger D, Bayon V. Societal costs of insomnia. *Sleep Med Rev.* 2010;14: 379-389.
27. Ohayon MM. Determining the level of sleepiness in the American population and its correlates. *J Psychiatr Res.* 2012;46: 422-427.
28. Cappuccio FP, D'Elia L, Strazzullo P, Miller MA. Sleep duration and all-cause mortality: a systematic review and meta-analysis of prospective studies. *Sleep.* 2010;33: 585-592.
29. Lavie P. Sleep-wake as a biological rhythm. *Annu Rev Psychol.* 2001;52: 277-303.
30. Innominato PF, Giacchetti S, Bjarnason GA, et al. Prediction of overall survival through circadian rest-activity monitoring during chemotherapy for metastatic colorectal cancer. *Int J Cancer.* 2012;131: 2684-2692.
31. Levi F, Dugue PA, Innominato P, et al. Wrist actimetry circadian rhythm as a robust predictor of colorectal cancer patients survival. *Chronobiol Int.* 2014: 1-10.
32. Innominato PF, Roche VP, Palesh OG, Ulusakarya A, Spiegel D, Levi FA. The circadian timing system in clinical oncology. *Ann Med.* 2014;46: 191-207.
33. Levi F, Okyar A, Dulong S, Innominato PF, Clairambault J. Circadian timing in cancer treatments. *Annu Rev Pharmacol Toxicol.* 2010;50: 377-421.
34. Palesh O, Aldridge-Gerry A, Zeitzer JM, et al. Actigraphy-Measured Sleep Disruption as a Predictor of Survival among Women with Advanced Breast Cancer. *Sleep.* 2014;37: 837-842.
35. Innominato PF, Giacchetti S, Moreau T, et al. Fatigue and weight loss predict survival on circadian chemotherapy for metastatic colorectal cancer. *Cancer.* 2013;119: 2564-2573.
36. Innominato PF, Giacchetti S, Moreau T, et al. Prediction of survival by neutropenia according to delivery schedule of oxaliplatin-5-Fluorouracil-leucovorin for metastatic colorectal cancer in a randomized international trial (EORTC 05963). *Chronobiol Int.* 2011;28: 586-600.
37. Innominato PF, Levi FA, Bjarnason GA. Chronotherapy and the molecular clock: Clinical implications in oncology. *Adv Drug Deliv Rev.* 2010;62: 979-1001.

38. Ortiz-Tudela E, Iurisci I, Beau J, et al. The circadian rest-activity rhythm, a potential safety pharmacology endpoint of cancer chemotherapy. *Int J Cancer*. 2014;134: 2717-2725.
39. Koller M, Aaronson NK, Blazeby J, et al. Translation procedures for standardised quality of life questionnaires: The European Organisation for Research and Treatment of Cancer (EORTC) approach. *Eur J Cancer*. 2007;43: 1810-1820.
40. Dibner C, Schibler U, Albrecht U. The Mammalian circadian timing system: organization and coordination of central and peripheral clocks. *Annu Rev Physiol*. 2010;72: 517-549.


Patients enrolled and randomized : N= 564  
(FOLFOX2 & chronoFLO4: N= 282 each)


Valid baseline sleep assessment: N= 505  
(FOLFOX2: N= 253; chronoFLO4: N= 252)

**CURRENT STUDY POPULATION**  
Valid 2<sup>nd</sup> sleep assessment on treatment: N= 361  
(FOLFOX2: N= 188; chronoFLO4: N= 173)




**Median follow-up: 89.2 months (range: 67.8 – 107.3 months)**  
Progressed: N= 342  
Died: N= 320  
Lost to follow-up: N= 19  
Alive for ≥5 years: N= 58






## At baseline



## On treatment



Sleep problems

— Yes

— No



